AQR Capital Management LLC Sells 91,596 Shares of PetMed Express, Inc. (NASDAQ:PETS)

AQR Capital Management LLC decreased its position in shares of PetMed Express, Inc. (NASDAQ:PETS) by 13.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 591,435 shares of the company’s stock after selling 91,596 shares during the quarter. AQR Capital Management LLC owned approximately 2.87% of PetMed Express worth $2,395,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new position in PetMed Express during the second quarter worth about $34,000. SG Americas Securities LLC purchased a new position in PetMed Express in the 2nd quarter valued at approximately $46,000. Marshall Wace LLP bought a new stake in PetMed Express during the 2nd quarter valued at $46,000. Oak Thistle LLC purchased a new stake in shares of PetMed Express during the first quarter worth $50,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new position in shares of PetMed Express in the first quarter worth $61,000. Hedge funds and other institutional investors own 73.33% of the company’s stock.

PetMed Express Price Performance

Shares of NASDAQ:PETS opened at $4.03 on Wednesday. The firm has a fifty day moving average price of $3.43 and a two-hundred day moving average price of $3.93. The company has a market cap of $83.05 million, a price-to-earnings ratio of -10.33 and a beta of 0.71. PetMed Express, Inc. has a one year low of $2.90 and a one year high of $10.60.

PetMed Express (NASDAQ:PETS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.30. The company had revenue of $67.95 million during the quarter, compared to analyst estimates of $77.52 million. PetMed Express had a negative return on equity of 3.44% and a negative net margin of 1.24%. Equities research analysts expect that PetMed Express, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Lake Street Capital reiterated a “hold” rating and set a $3.50 price objective (down from $7.00) on shares of PetMed Express in a research note on Wednesday, August 7th. Morgan Stanley reduced their target price on PetMed Express from $6.50 to $3.50 and set an “underweight” rating for the company in a report on Wednesday, June 12th.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.